RxDoctor Payments DataLook up a doctor →

Alexis Cruz Chacon, MD

Hematology & Oncology · San Juan, PRNPI 1083898969

Payments from drug & device makers

$504,797in general payments, 2019–2025

Across 1,180 payments — averaging $427.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$123K
  • Amgen$88K
  • Johnson & Johnson$78K
  • GSK$58K
  • Sanofi$44K
  • Takeda Pharmaceuticals U.S.A., Inc.$40K
  • plus $73K from 54 others

What the payments were for

  • Consulting fees$31,8247%
  • Speaking & faculty fees$381,83085%
  • Travel & lodging$6,4681%
  • Food & beverage$29,0336%
  • Education$1,2770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie130$123,061
Amgen113$88,300
Johnson & Johnson(2 entities)154$77,996
GSK51$58,471
Sanofi63$44,231
Takeda Pharmaceuticals U.S.A., Inc.30$39,897
E.r. Squibb & Sons, L.L.C.83$18,518
Bristol Myers Squibb16$16,571
Taiho Oncology, Inc.21$14,678
AstraZeneca(2 entities)60$3,829
Sanofi-aventis U.S. LLC17$3,476
Rigel Pharmaceuticals, Inc.12$2,871
Merck17$1,780
Novartis71$1,702
Astellas Pharma US Inc22$720
Gilead8$718
Genentech USA, Inc.37$693
Eli Lilly Export S.A. Puerto Rico Branch28$641
Tempus AI, Inc25$629
PBG Puerto Rico LLC30$606
Adaptive Biotechnologies Corporation12$572
Pfizer25$550
Incyte Corporation23$514
Syndax Pharmaceuticals, Inc.3$502
Sobi, Inc15$462
Jazz Pharmaceuticals Inc.11$241
Beigene USA, Inc.11$241
Karyopharm Therapeutics Inc.4$238
Seagen Inc.8$234
ADC Therapeutics America, Inc.8$191
Eisai Inc.9$178
CTI Biopharma Corp.1$145
Genentech, Inc.1$124
Regeneron Healthcare Solutions, Inc.5$108
Exelixis Inc.5$102
Ipsen Biopharmaceuticals, Inc4$97
Pharmacyclics LLC, An Abbvie Company5$88
Partner Therapeutics, Inc.5$87
Genmab U.S., Inc.4$82
Clovis Oncology, Inc.4$75
Bayer4$71
Beone Medicines USA, Inc.3$60
Servier Pharmaceuticals LLC3$56
Morphosys, US Inc.2$47
AVEO Pharmaceuticals, Inc.2$46
Telix Pharmaceuticals1$25
Mirati Therapeutics, Inc.1$25
Global Blood Therapeutics, Inc.1$24
Kyowa Kirin, Inc.1$22
Shire North American Group Inc1$21
Blueprint Medicines Corporation1$20
Spectrum Pharmaceuticals Inc.1$20
Lantheus Medical Imaging, Inc.1$19
Verity Pharmaceuticals Inc.1$19
Caris MPI, Inc.1$18
Verastem, Inc.1$18
Agios Pharmaceuticals, Inc.1$18
Pfizer Pharmaceuticals LLC1$17
Kadmon Pharmaceuticals LLC1$17
Puma Biotechnology, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$504,797 in reported general payments places this provider in the 90th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,897
Medicare patients
31
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide127$2,279,883
PomalystPomalidomide70$1,610,122
PromactaEltrombopag Olamine35$1,265,952
IdhifaEnasidenib Mesylate27$916,319
RezurockBelumosudil Mesylate43$773,826
SprycelDasatinib46$742,375
JakafiRuxolitinib Phosphate46$699,219
NinlaroIxazomib Citrate44$574,090
TibsovoIvosidenib14$470,259
IclusigPonatinib Hcl14$290,762
ScemblixAsciminib Hydrochloride12$256,891
VanflytaQuizartinib Dihydrochloride16$243,078
VenclextaVenetoclax25$221,018
ReblozylLuspatercept-Aamt14$137,814
InqoviDecitabine/Cedazuridine14$115,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid, Idhifa$16,571$3,196,202154 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel, Reblozyl$18,518$2,490,312130 claims
NovartisPromacta, Scemblix$1,702$1,522,84247 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Iclusig$39,897$864,85258 claims
Sanofi-aventis U.S. LLCRezurock$3,476$773,82643 claims
Incyte CorporationJakafi$514$699,21946 claims
Servier Pharmaceuticals LLCTibsovo$56$470,25914 claims
AbbVieVenclexta$123,061$221,01825 claims
Taiho Oncology, Inc.Inqovi$14,678$115,55814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →